| 主权项 |
1. A vaccine comprising at least one peptide consisting of 9 to 25 amino acid residues having the amino acid sequence(SEQ ID No. 1)X1X2X3WX4X5X6RX7(X8)m(X9)n, wherein X1 is an amino acid residue selected from the group of uncharged amino acid residues, X2 is an amino acid residue selected from the group of uncharged amino acid residues, X3 is an amino acid residue selected from the group of uncharged amino acid residues, X4 is an amino acid residue selected from the group consisting of asparagine, serine, alanine, glutamine and aspartic acid, X5 is an amino acid residue selected from the group consisting of leucine, glycine, alanine, tyrosine, aspartic acid, phenylalanine and valine, X6 is an amino acid residue selected from the group of hydrophilic, negatively charged amino acid residues, X7 is an amino acid residue selected from the group of uncharged amino acid residues, X8 is an amino acid residue selected from the group of uncharged amino acid residues selected from the group consisting of threonine, leucine, glutamine, alanine and serine, X9 is X10X11X12 or a C-terminal truncated fragment thereof consisting of 1 or 2 amino acid residues, X10 is an amino acid residue, preferably an amino acid residue selected from the group of uncharged amino acid residues, X11 is an amino acid residue, X12 is an amino acid residue, m is 0 or 1, n is 0 or 1, and SEQ ID No. 1 is not SIPWNLERITPPR or a C-terminal truncated fragment thereof, and wherein the at least one peptide is coupled or fused to a pharmaceutically acceptable carrier. |
